March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
September 2023 in “Journal of the American Academy of Dermatology” August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
70 citations
,
February 2018 in “Seminars in Arthritis and Rheumatism” Belimumab reduces disease activity, steroid use, and flares in lupus patients.
72 citations
,
March 2023 in “Biomolecules” Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
15 citations
,
January 2019 in “Journal of the Formosan Medical Association” Adalimumab helped control a child's severe eye disease when other treatments failed.
9 citations
,
January 2024 in “International Journal of Dermatology”
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
November 2024 in “Journal of Investigative Dermatology” 19 citations
,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” Dupilumab is effective and safe for treating moderate-to-severe atopic dermatitis in adolescents.
1 citations
,
October 2023 in “European Journal of Dermatology” Combining hair transplantation with PRP is more effective for treating hair loss than hair transplantation alone.
Belimumab effectively controls SLE disease activity and reduces steroid use.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
4 citations
,
September 2024 in “BMC Cancer” January 2026 in “Journal of Investigative Dermatology” 3D imaging effectively tracks skin changes in vitiligo treatment.
Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
October 2018 in “The American journal of gastroenterology” Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
1 citations
,
October 2021 in “Deleted Journal” Dupilumab can help regrow hair and improve skin conditions in patients with severe atopic dermatitis and alopecia areata.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab in treating psoriasis.
August 2019 in “Reactions Weekly” Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.
7 citations
,
July 2021 in “JAAD case reports” Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.
3 citations
,
August 2024 in “British Journal of Dermatology” Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.
December 2013 in “Nursing2023” The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.